Special Issue "Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 24377
Interests: canceromics; cancer metabolic reprogramming; gene therapy; tumor nitrogen metabolism
2. Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain
Interests: antioxidant enzymes; cancer metabolism; combined therapies against cancer; oxidative stress; ROS; tumor-specific isoenzymes
Cancer cells have metabolic requirements that separate them from normal cells and render them vulnerable to drugs that target these processes. The altered metabolism exhibited by most tumor cells is a hallmark of cancer. Pioneering works studying the differential metabolic traits of cancer cells firstly classified tumors as glucose and nitrogen traps, thus reflecting their ability to avidly consume both nutrients. In recent years, metabolic studies using omics technologies are more precisely unveiling the tumor metabolome and cancer-specific metabolomic signatures.
Despite the sound advances in knowledge and the rapid progress in the field of cancer metabolic reprogramming, this information needs to be translated into a more successful class of cancer therapeutic strategies. Furthermore, the mechanims that control the metabolic phenotype of specific tumors have not been fully understood, and the biological functions of many cancer-relevant proteins have yet to be explored. These issues need to be addressed in order to improve drug design and to overcome the drug resistance phenomenon frequently found in cancer therapy. In this Special Issue of Cancers, we aim to stimulate discussions on these topics, whilst allowing an updated account of relevant works on the tumor metabolome by bringing together expert opinions from across the field. We welcome submissions that cover any relevant topic, including metabolite addiction in cancer cells, cancer metabolic rewiring, cancer metabolic remodelling by tumor-specific isoenzymes, cancer-specific bionergetic alterations, new metabolic functions of tumor suppresor genes and oncogenes, mechanisms of metabolic dysregulation in cancers, and new therapeutic approaches targeting cancer metabolism.
Prof. Dr. Javier Marquez
Prof. Dr. José M. Matés
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Tumor metabolome
- Cancer metabolic reprogramming
- Tumor-specific isoenzymes
- Cancer biomarkers
- Therapeutic targets